These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19810096)

  • 1. Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer.
    Tominaga T; Iwahashi M; Takifuji K; Hotta T; Yokoyama S; Matsuda K; Higashiguchi T; Oku Y; Nasu T; Yamaue H
    Int J Cancer; 2010 Apr; 126(7):1691-701. PubMed ID: 19810096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
    Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
    BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
    Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y
    Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX.
    Nehls O; Okech T; Hsieh CJ; Enzinger T; Sarbia M; Borchard F; Gruenagel HH; Gaco V; Hass HG; Arkenau HT; Hartmann JT; Porschen R; Gregor M; Klump B
    Br J Cancer; 2007 May; 96(9):1409-18. PubMed ID: 17426704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
    Mirjolet JF; Barberi-Heyob M; Didelot C; Peyrat JP; Abecassis J; Millon R; Merlin JL
    Br J Cancer; 2000 Nov; 83(10):1380-6. PubMed ID: 11044365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
    Ichikawa W; Ooyama A; Toda E; Sugimoto Y; Oka T; Takahashi T; Shimizu M; Sasaki Y; Hirayama R
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):794-801. PubMed ID: 16528528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells.
    Zheng M; Wang H; Zhang H; Ou Q; Shen B; Li N; Yu B
    J Cancer Res Clin Oncol; 1999; 125(6):357-60. PubMed ID: 10363568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
    Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
    Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
    Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
    Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
    Yao J; Huang A; Zheng X; Liu T; Lin Z; Zhang S; Yang Q; Zhang T; Ma H
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):419-431. PubMed ID: 27838786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
    Cohen V; Panet-Raymond V; Sabbaghian N; Morin I; Batist G; Rozen R
    Clin Cancer Res; 2003 May; 9(5):1611-5. PubMed ID: 12738713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs.
    Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
    Oncol Rep; 2005 Sep; 14(3):609-15. PubMed ID: 16077963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
    Liang JT; Huang KC; Cheng YM; Hsu HC; Cheng AL; Hsu CH; Yeh KH; Wang SM; Chang KJ
    Int J Cancer; 2002 Feb; 97(4):451-7. PubMed ID: 11802206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins.
    Nita ME; Nagawa H; Tominaga O; Tsuno N; Fujii S; Sasaki S; Fu CG; Takenoue T; Tsuruo T; Muto T
    Br J Cancer; 1998 Oct; 78(8):986-92. PubMed ID: 9792140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
    Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
    Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells.
    Nishida N; Yamashita S; Mimori K; Sudo T; Tanaka F; Shibata K; Yamamoto H; Ishii H; Doki Y; Mori M
    Ann Surg Oncol; 2012 Sep; 19(9):3065-71. PubMed ID: 22322955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nobiletin induces apoptosis and potentiates the effects of the anticancer drug 5-fluorouracil in p53-mutated SNU-16 human gastric cancer cells.
    Moon JY; Cho M; Ahn KS; Cho SK
    Nutr Cancer; 2013; 65(2):286-95. PubMed ID: 23441616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
    Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy.
    Huang ZH; Hua D; Li LH; Zhu JD
    J Cancer Res Clin Oncol; 2008 Oct; 134(10):1129-34. PubMed ID: 18357466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas.
    Benhattar J; Cerottini JP; Saraga E; Metthez G; Givel JC
    Int J Cancer; 1996 Jun; 69(3):190-2. PubMed ID: 8682586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.